Nanomedicine enhances mitochondrial health and reduces aging effects in neurodegenerative conditions, implying therapeutic potential.
Nanomaterials have been widely used to scavenge reactive oxygen species (ROS) and relieve mitochondria oxidative damage. However, developing nanomedicines that not only remove ROS but also accelerate the repair of dysfunctional mitochondria remains challenging. This study identifies polyvinylpyrrolidone (PVP)‐modified palladium nanoparticles (PdP NPs) as mimics of cytochrome c oxidase (C c O) and superoxide dismutase (SOD), showcasing their potential as multifunctional nanoreactors to activate mitochondria for aging alleviation and neuroprotection. PdP NPs treatment enhances mitochondrial respiratory chain function, scavenges excessive ROS, thus alleviates cellular energy scarcity of aging individuals. Additionally, PdP NPs improve mitochondrial dynamics, promote biogenesis, and induce mitochondrial unfolded protein response (UPR mt ), strengthening mitochondrial integrity and homeostasis for better therapeutic outcomes. In vivo evaluations reveal significant anti‐aging effects, with the nanozymes notably reducing neurodegeneration and improving neuronal survival. This work highlights PdP NPs as a multifunctional nanotherapeutic platform capable of rewiring mitochondrial metabolism and homeostasis, offering a promising strategy for aging‐related disease management.
No takes yet. Share an insight, caveat, or question.
Cong et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: